What's Going On With Zimmer Biomet Shares After Q1 Earnings?
What's Going On With Zimmer Biomet Shares After Q1 Earnings?
Zimmer Biomet Holdings, Inc. (NYSE:ZBH) reported first-quarter adjusted earnings per share of $1.94, beating the street view of $1.87.
Zimmer Biomet Holdings, Inc.（紐約證券交易所代碼：ZBH）公佈的第一季度調整後每股收益爲1.94美元，超過了街景的1.87美元。
The company reported quarterly sales of $1.889 billion, beating the analyst consensus of $1.869 billion.
該公司公佈的季度銷售額爲18.89億美元，超過了分析師共識的18.69億美元。
Quarterly sales rose 3.2% year over year and 4.4% on a constant currency basis.
季度銷售額同比增長3.2％，按固定貨幣計算增長4.4％。
Geographically, sales within the U.S. grew 3.7% year over year, while international sales rose 2.5%.
從地域上看，美國境內的銷售額同比增長3.7％，而國際銷售額增長2.5％。
Segment-wise, revenues gained 3.4% in the Knees segment and fell 0.3% in the Hips unit. Sales from Sports Medicine, Extremities, Trauma, Craniomaxillofacial, and Thoracic unit gained 4.4% year over year.
細分市場方面，膝蓋板塊的收入增長了3.4％，臀部部門的收入下降了0.3％。運動醫學、四肢、創傷、顱頜面和胸科的銷售額同比增長4.4％。
The company highlighted that it received U.S. Food and Drug Administration 510(k) clearance for the ROSA Shoulder System – the world's first robotic assistant for shoulder replacement surgery- and announced that the first surgery was successfully completed in April at Mayo Clinic.
該公司強調，其全球首款肩部置換手術機器人助手ROSA Shoulder System已獲得美國食品藥品監督管理局的510（k）許可，並宣佈首例手術於4月在梅奧診所成功完成。
Zimmer Biomet also received U.S. FDA 510(k) clearance for the Z1 Femoral Hip Stem, which is expected to launch later this year.
Zimmer Biomet還獲得了美國食品藥品管理局的510（k）許可，該產品預計將於今年晚些時候上市。
Outlook: The company reiterated adjusted diluted EPS for FY24 of $8-$8.15 versus the street view of $8.06.
展望：該公司重申24財年調整後的攤薄每股收益爲8-8.15美元，而街景爲8.06美元。
Zimmer Biomet expects Constant currency revenue change for FY24 in the range of 5%-6%.
Zimmer Biomet預計，24財年的貨幣收入將持續變化在5％-6％之間。
Price Action: ZBH shares are trading lower by 1.16% to $118.18 at last check Thursday.
價格走勢：週四最後一次檢查時，ZBH股價下跌1.16％，至118.18美元。
Photo via Wikimedia Commons
照片來自維基共享資源
譯文內容由第三人軟體翻譯。